Indrayani Biotech

Chennai, India Founded: 1992 • Age: 34 yrs Listed
Diversified crop nutrition and protection solutions are provided for farmers.

About Indrayani Biotech

Indrayani Biotech is a publicly listed company based in Chennai (India) founded in 1992. Diversified crop nutrition and protection solutions are provided for farmers. The company has 445 employees. Its Indian entity Indrayani Biotech Limited reported revenue of β‚Ή142 Cr. Indrayani Biotech offers products and services including Bio-Fertilizers, Bio-pest Controllers, and Contract Catering. Its focus areas include Food and Agriculture Tech, Crop Tech, Farm Inputs and Biologicals. Its competitors include IPL Biologicals, Titan Biotech and Univia; 2 of its 3 listed competitors have raised funding.

Company details

Founded in 1992 and based in Chennai, India, operations focus on the agricultural biotechnology sector. Bio fertilizers, bio pesticides, bio fungicides, and bio tonics are offered for field crop protection and nutrition. Neem-based compost is included in the product range. Turnkey projects and consultancy services are also provided to support farming needs.

  • Headquarters Chennai, India
  • Employees 445
  • Stage Public
  • Sectors
    Agriculture
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website indrayani.com
  • Legal Name Indrayani Biotech Ltd.
Operational Areas
Key Metrics
  • Market Cap
    ₹73.53 Cr

    INDRANIB · BSE

  • Share Price
    ₹9.88

    +4.88% today

  • Revenue
    ₹138 Cr

    FY 2025-26 · +5.8% YoY

  • EBITDA
    ₹9.63 Cr

    Margin 7.0%

  • Net Profit
    ₹2.16 Cr

    FY 2025-26 · +135.4% YoY

  • P/E (TTM)
    34.5x

    P/B 0.6x

  • Employee Count
    445

Products & Services of Indrayani Biotech

Indrayani Biotech offers a comprehensive portfolio of products and services, including Bio-Fertilizers, Bio-pest Controllers, and Contract Catering.

Bio-Fertilizers
Agri Products

Microorganism-based fertilizers for enhancing soil and crop growth.

Bio-pest Controllers
Agri Products

Products using microorganisms to control pests in agriculture.

Contract Catering
Food Services

Services for corporate administrative and hospitality needs.

Board of directors of Indrayani Biotech Limited (Indrayani Biotech)

Indrayani Biotech Limited is the primary company behind Indrayani Biotech. The boards of the 2 registered companies of Indrayani Biotech currently have 7 directors; the longest-serving is Nangavaram Mahadevan Ranganathan, appointed in 2018. 26 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Nangavaram Mahadevan Ranganathan
DIN 06377402
Director20 Aug 20188 yrs 2 moIndrayani Biotech Limited
Kannimangalam Subramanyan Vaidyanathan
DIN 01122393
Director20 Aug 20188 yrs 2 moIndrayani Biotech Limited
Swaminathan Govindarajan
DIN 02481041
Whole-time director01 Aug 20206 yrs 3 moIndrayani Biotech Limited
Muthukrishnan Ramesh
DIN 01016291
Whole-time director04 Jan 20215 yrs 10 moIndrayani Biotech Limited
Bokara Nagarajan Padmaja Priyadarshini
DIN 06416242
Director26 Mar 20215 yrs 7 moIndrayani Biotech Limited
Kasiraman Sayee Sundar
DIN 01295584
Designated Partner24 Feb 20224 yrs 8 moIbl Laksha Hospitals Llp, Indrayani Biotech Limited
Dhinakaran Rajagopal
DIN 09115326
Designated Partner17 Feb 20251 yr 8 moIbl Laksha Hospitals Llp

People of Indrayani Biotech

1 people are tracked at Indrayani Biotech (1 in leadership); the tracked headcount is 445.

NameRoleGroup
Managing DirectorLeadership
Premium access

Complete people profiles for Indrayani Biotech

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Indrayani Biotech

Indrayani Biotech is a publicly listed company on the BSE with ticker symbol INDRANIB in India, operating in the Consumer services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date17 May 1994
  • Listed onBSE: 526445
  • Listed entityIndrayani Biotech Ltd.
  • Exchange sectorConsumer services
  • ISININE007C01021
  • Share price₹8.39 (-1.18% on the day) · 2026-10-14
  • Market capitalisation₹38.7 Cr
  • Price to earnings14.4
  • EPS (diluted, trailing year)₹0.58
  • Volume (last session)114,198

Financials of Indrayani Biotech

Exchange-reported figures of Indrayani Biotech Limited, the listed company behind Indrayani Biotech (BSE: INDRANIB).

Financial Highlights

FY 2025-26 Β· Consolidated
Revenue
₹138 Cr
+5.8% YoY
EBITDA
₹9.63 Cr
+50.9% YoY
Profit After Tax
₹2.16 Cr
+135.4% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue13813016616361.5721.0949.90
Revenue growth+5.8%-21.7%+2.0%+164.6%+191.9%-57.7%-
EBITDA9.636.3823.6616.826.78(9.05)2.77
EBITDA margin+7.0%+4.9%+14.2%+10.3%+11.0%-42.9%+5.6%
Profit before tax0.30(5.74)10.9712.324.45(11.21)0.81
Net profit2.16(6.10)6.369.244.45(7.10)0.81
Net profit margin+1.6%-4.7%+3.8%+5.7%+7.2%-33.7%+1.6%
EPS (β‚Ή)0.48(1.34)1.402.551.30(3.28)2.22
Balance sheet
Total assets-23718911943.3635.6244.58
Net worth-72.5267.2255.0924.1719.7230.83
Total debt-13711370.1918.8015.5413.74
Cash & bank-0.290.583.041.500.681.40
Net working capital-14799.7740.1110.884.7312.30
Cash flow
Cash from operations-(6.74)(30.35)16.194.110.265.96
Cash from investing-24.74(16.34)(47.39)(0.56)(0.70)(3.67)
Cash from financing-(18.30)44.2432.74(2.73)(0.28)(1.28)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue37.7137.7635.0135.9529.1050.5717.3230.81
Revenue growth (YoY)+29.6%-25.3%+102.1%+16.7%-7.7%+14.0%--
Other income1.590.880.831.801.062.780.000.30
EBITDA1.472.212.782.452.18(5.74)2.925.10
EBITDA margin+3.9%+5.9%+7.9%+6.8%+7.5%-11.4%+16.9%+16.6%
Depreciation1.101.131.011.300.86(1.72)1.462.79
Interest1.373.082.471.892.177.071.031.42
Profit before tax0.59(1.12)0.131.060.21(8.31)0.431.19
Tax0.05(2.08)0.030.150.050.210.08(0.02)
Net profit0.540.960.100.910.16(8.52)0.351.21
EPS (β‚Ή)0.060.240.030.090.03(1.88)0.050.13
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue21.9037.7762.3274.4857.9921.0149.90
Revenue growth-42.0%-39.4%-16.3%+28.4%+176.0%-57.9%-
EBITDA1.585.565.808.236.25(8.77)2.77
EBITDA margin+7.2%+14.7%+9.3%+11.1%+10.8%-41.7%+5.6%
Profit before tax1.200.663.015.094.24(10.88)0.81
Net profit0.701.461.465.574.24(6.77)0.81
Net profit margin+3.2%+3.9%+2.3%+7.5%+7.3%-32.2%+1.6%
EPS (β‚Ή)0.150.320.321.481.23(3.18)2.22
Balance sheet
Total assets-11711893.8640.9135.3844.58
Net worth-55.3454.5251.1524.1819.9530.83
Total debt-61.6663.4642.7116.7315.4313.74
Cash & bank-0.060.260.621.450.631.40
Net working capital-67.1664.4942.919.494.5812.30
Cash flow
Cash from operations-17.3526.098.333.470.525.96
Cash from investing-(1.34)(7.26)(14.09)0.59(0.56)(3.67)
Cash from financing-(16.22)(19.19)4.93(3.23)(0.73)(1.28)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4.154.085.205.936.699.288.199.51
Revenue growth (YoY)-38.0%-56.0%-36.5%-37.6%-38.0%-41.3%--
Other income0.190.820.681.820.890.930.660.89
Total expenses3.263.884.545.975.947.566.868.07
EBITDA0.890.200.66(0.04)0.751.721.331.44
EBITDA margin+21.4%+4.9%+12.7%-0.7%+11.2%+18.5%+16.2%+15.1%
Depreciation0.120.180.140.170.150.060.320.32
Interest0.760.541.090.991.322.391.521.89
Profit before tax0.200.300.110.620.170.200.150.12
Tax0.050.280.030.160.04(0.91)0.040.03

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 17 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue37.7137.7635.0135.9529.1050.5717.3230.81
Revenue growth (YoY)+29.6%-25.3%+102.1%+16.7%-7.7%+14.0%--
Other income1.590.880.831.801.062.780.000.30
EBITDA1.472.212.782.452.18(5.74)2.925.10
EBITDA margin+3.9%+5.9%+7.9%+6.8%+7.5%-11.4%+16.9%+16.6%
Depreciation1.101.131.011.300.86(1.72)1.462.79
Interest1.373.082.471.892.177.071.031.42
Profit before tax0.59(1.12)0.131.060.21(8.31)0.431.19
Tax0.05(2.08)0.030.150.050.210.08(0.02)
Net profit0.540.960.100.910.16(8.52)0.351.21
EPS (β‚Ή)0.060.240.030.090.03(1.88)0.050.13
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue13813016616361.5721.0949.90
Revenue growth+5.8%-21.7%+2.0%+164.6%+191.9%-57.7%-
Other income4.573.131.214.490.220.270.20
Total expenses12812414314654.7930.1447.13
Employee cost0.0019.6923.0723.019.585.3910.81
EBITDA9.636.3823.6616.826.78(9.05)2.77
EBITDA margin+7.0%+4.9%+14.2%+10.3%+11.0%-42.9%+5.6%
Depreciation4.303.373.803.350.660.461.01
Interest9.6011.8810.105.641.891.971.15
Profit before tax0.30(5.74)10.9712.324.45(11.21)0.81
Tax(1.86)0.360.550.370.000.000.00
Net profit2.16(6.10)6.369.244.45(7.10)0.81
Net profit margin+1.6%-4.7%+3.8%+5.7%+7.2%-33.7%+1.6%
EPS (β‚Ή)0.48(1.34)1.402.551.30(3.28)2.22
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-45.5445.5443.4834.2334.233.64
Reserves & surplus-23.4917.5610.07(10.06)(14.51)(3.39)
Shareholders' funds (net worth)-72.5267.2255.0924.1719.7230.83
Minority interest-27.419.05(6.73)0.410.360.00
Secured loans-13510862.7517.8915.5413.05
Unsecured loans-1.644.867.440.910.000.69
Total debt-13711370.1918.8015.5413.74
Total liabilities-23718911943.3635.6244.58
Assets
Gross block-10210288.8658.1916.8518.38
Net block-57.6862.4257.4816.5115.3817.37
Capital work in progress-25.6720.3013.7413.2713.7213.59
Investments-0.250.220.220.000.010.01
Inventories-41.3442.3512.211.531.095.07
Sundry debtors-58.6939.5329.9714.104.777.04
Cash & bank balances-0.290.583.041.500.681.40
Loans & advances-77.6262.5232.301.782.625.68
Total current assets-17814577.5218.919.1619.19
Total current liabilities-30.8245.2137.418.034.436.89
Net working capital-14799.7740.1110.884.7312.30
Total assets-23718911943.3635.6244.58
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-0.583.041.500.681.400.39
Net cash from operating activities-(6.74)(30.35)16.194.110.265.96
Net cash from investing activities-24.74(16.34)(47.39)(0.56)(0.70)(3.67)
Net cash from financing activities-(18.30)44.2432.74(2.73)(0.28)(1.28)
Net change in cash-(0.29)(2.45)1.530.82(0.72)1.01
Closing cash-0.290.583.041.500.681.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+5.8%-21.7%+2.0%+164.6%+191.9%-57.7%-
EBITDA growth+50.9%-73.0%+40.7%+148.1%+174.9%-426.7%-
PBT growth+9998.0%--11.0%+176.9%+9998.0%-+9997.0%
Net income growth+135.4%-195.9%-31.2%+107.6%+162.7%-976.5%-
Revenue CAGR (3Y)-5.4%+28.4%+99.0%+48.4%---
EBITDA CAGR (3Y)-17.0%-2.0%-+82.4%---
Profitability & leverage
Net income margin+1.6%-4.7%+6.3%+7.3%+7.2%-53.2%+1.6%
Return on capital employed-+3.2%+13.8%+20.0%+14.3%0.0%+4.1%
Return on net worth--8.8%+18.2%+29.3%+16.5%0.0%+2.4%
Debt / equity-1.791.491.120.780.580.45
Long-term debt / equity-0.970.870.540.350.300.23
Interest cover180.11394.6850.8641.8730.88-20.7265.34
Efficiency & per share
Fixed asset turnover-1.281.752.221.641.202.71
Inventory turnover-3.116.0923.7247.006.859.84
Debtors turnover-2.654.787.396.533.577.09
EPS (β‚Ή)0.48(1.34)1.402.551.30(3.28)2.22
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)0.0015.1613.8612.947.065.760.70
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue4.154.085.205.936.699.288.199.51
Revenue growth (YoY)-38.0%-56.0%-36.5%-37.6%-38.0%-41.3%--
Other income0.190.820.681.820.890.930.660.89
Total expenses3.263.884.545.975.947.566.868.07
EBITDA0.890.200.66(0.04)0.751.721.331.44
EBITDA margin+21.4%+4.9%+12.7%-0.7%+11.2%+18.5%+16.2%+15.1%
Depreciation0.120.180.140.170.150.060.320.32
Interest0.760.541.090.991.322.391.521.89
Profit before tax0.200.300.110.620.170.200.150.12
Tax0.050.280.030.160.04(0.91)0.040.03
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue21.9037.7762.3274.4857.9921.0149.90
Revenue growth-42.0%-39.4%-16.3%+28.4%+176.0%-57.9%-
Other income4.213.523.620.640.220.260.20
Total expenses20.3232.2156.5266.2551.7429.7847.13
Employee cost0.0012.8615.2317.108.485.2210.81
EBITDA1.585.565.808.236.25(8.77)2.77
EBITDA margin+7.2%+14.7%+9.3%+11.1%+10.8%-41.7%+5.6%
Depreciation0.641.021.450.930.340.401.01
Interest3.957.404.962.851.891.971.15
Profit before tax1.200.663.015.094.24(10.88)0.81
Tax0.50(0.80)1.550.020.000.000.00
Net profit0.701.461.465.574.24(6.77)0.81
Net profit margin+3.2%+3.9%+2.3%+7.5%+7.3%-32.2%+1.6%
EPS (β‚Ή)0.150.320.321.481.23(3.18)2.22
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-45.5445.5443.4834.2334.233.64
Reserves & surplus-6.314.866.13(10.05)(14.28)(3.39)
Shareholders' funds (net worth)-55.3454.5251.1524.1819.9530.83
Secured loans-61.6658.6035.2716.7315.4313.05
Unsecured loans-0.004.867.440.000.000.69
Total debt-61.6663.4642.7116.7315.4313.74
Total liabilities-11711893.8640.9135.3844.58
Assets
Gross block-20.5325.8026.5017.0916.5318.38
Net block-16.6621.6623.8115.3315.1117.37
Capital work in progress-18.0918.0312.7213.2213.7213.59
Investments-9.619.567.990.190.190.01
Inventories-1.691.921.861.371.085.07
Sundry debtors-16.4617.6016.2312.884.777.04
Cash & bank balances-0.060.260.621.450.631.40
Loans & advances-62.4251.7230.622.312.565.68
Total current assets-80.6371.5049.3318.019.0419.19
Total current liabilities-13.477.016.428.524.466.89
Net working capital-67.1664.4942.919.494.5812.30
Total assets-11711893.8640.9135.3844.58
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-0.260.621.450.631.400.39
Net cash from operating activities-17.3526.098.333.470.525.96
Net cash from investing activities-(1.34)(7.26)(14.09)0.59(0.56)(3.67)
Net cash from financing activities-(16.22)(19.19)4.93(3.23)(0.73)(1.28)
Net change in cash-(0.20)(0.36)(0.83)0.82(0.78)1.01
Closing cash-0.060.260.621.450.631.40
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-42.0%-39.4%-16.3%+28.4%+176.0%-57.9%-
EBITDA growth-71.6%-4.1%-29.5%+31.7%+171.3%-416.6%-
PBT growth+81.8%-78.1%-40.9%+20.1%+9998.0%-+9998.0%
Net income growth-52.1%0.0%-73.8%+31.4%+162.6%-935.8%-
Revenue CAGR (3Y)-33.5%-13.3%+43.7%+14.3%---
EBITDA CAGR (3Y)-42.3%-3.8%-+43.8%-+307.1%-
Profitability & leverage
Net income margin+3.2%+3.9%+2.3%+6.8%+7.3%-51.8%+1.6%
Return on capital employed-+6.7%+7.2%+10.6%+14.2%0.0%+8.2%
Return on net worth-+2.5%+2.8%+12.5%+15.6%0.0%+4.8%
Debt / equity-1.141.000.790.730.570.48
Long-term debt / equity-0.300.330.300.340.300.25
Interest cover420.21163.00114.0239.0431.98-21.4865.34
Efficiency & per share
Fixed asset turnover-1.632.383.423.451.205.43
Inventory turnover-20.9332.9746.1247.346.8319.68
Debtors turnover-2.223.685.126.573.5614.18
EPS (β‚Ή)0.150.320.321.481.23(3.18)2.22
Dividend per share (β‚Ή)0.000.000.000.000.000.000.00
Book value per share (β‚Ή)0.0011.3911.0711.797.065.830.70

Competitors of Indrayani Biotech

Indrayani Biotech has 3 listed competitors in our database, 2 of them funded. They include IPL Biologicals, Titan Biotech and Univia.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
iplbiologicals.com1994Gurugram, India$4.66M901
Plant nutrition and protection products are manufactured and supplied.
titanbiotechltd.com1992Delhi, India406
Biological products are manufactured and exported for various industries.
univia.in2020Ahmedabad, India$237,83852
Agri-input retailers are connected to farmers via a phygital network.
Premium access

Detailed competitors of Indrayani Biotech

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Indrayani Biotech

The website of Indrayani Biotech (indrayani.com) receives about 1.1K visits a month.

  • Monthly visits
    1.1K

    ▲ 9.7% vs previous month

Similar websites

Websites whose visitors overlap most with Indrayani Biotech. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
google.com
100%
85.8B#1View details
indiabiotech.in
indiabiotech.in
68%
–

Top companies in Crop Tech & Equipment

3 companies that operate in the same segment as Indrayani Biotech (Crop Tech & Equipment) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Provider of climate-smart deeptech solutions for renewable energy and sustainable agriculture
2010Pune, Maharashtra, IndiaUSD 76.38 MUSD 56.11 M702
Manufacturer and distributor of irrigation equipment
1963Jalgaon, Maharashtra, IndiaUSD 679.04 M2,764
AgroStar is engaged in providing agricultural products and solutions.
2013Pune, Maharashtra, IndiaUSD 208.82 MUSD 104.54 M1,456
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Indrayani Biotech

Premium access

Complete news archive for Indrayani Biotech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Indrayani Biotech

Indrayani Biotech was founded in 1992.

Indrayani Biotech is headquartered in Chennai, India. It is registered at Chennai, Tamil Nadu, India.

Indrayani Biotech has 445 employees.

The primary company behind Indrayani Biotech, Indrayani Biotech Limited, reported revenue of β‚Ή142 Cr for FY 2026, up 6% year on year.

Founded in 1992 and based in Chennai, India, operations focus on the agricultural biotechnology sector. Bio fertilizers, bio pesticides, bio fungicides, and bio tonics are offered for field crop protection and nutrition. Neem-based compost is included in the product range. Turnkey projects and consultancy services are also provided to support farming needs.

Indrayani Biotech's top competitors include Titan Biotech, IPL Biologicals and Univia.

Indrayani Biotech offers Bio-Fertilizers, Bio-pest Controllers, and Contract Catering.

Yes, Indrayani Biotech is publicly traded on BSE under the ticker symbol INDRANIB.

Indrayani Biotech is associated with 2 legal entities: Indrayani Biotech Limited, Ibl Laksha Hospitals Llp.

The legal entities of Indrayani Biotech currently have 8 directors, including Dhinakaran Rajagopal, Kasiraman Sayee Sundar, Nangavaram Mahadevan Ranganathan and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available